*Primecap Management Company Holds Stake in Biogen INC (BIIB)

May 16, 2018 - By Michele Cranor

Biogen Inc. (NASDAQ:BIIB) Corporate LogoBig Money Sentiment increased to 1.17 in Q4 2017. It has change of 0.04, from 2017Q3’s 1.13. The ratio is positive due to BIIB positioning: 46 sold and 305 reduced. 105 funds acquired holdings and 305 increased holdings. Investors holded 181.16 million in 2017Q3 but now own 180.65 million shares or 0.28% less. Teachers Insur And Annuity Association Of America stated it has 1,924 shs. Eads & Heald Inv Counsel has invested 0.15% in Biogen Inc. (NASDAQ:BIIB). Twin Capital Management reported 0.54% stake. British Columbia Invest Management Corporation holds 0.36% in Biogen Inc. (NASDAQ:BIIB) or 160,230 shs. Charter Tru holds 0.12% or 3,119 shs in its capital. Altrinsic Global Advsr Lc owns 92,121 shs for 1.13% of their capital. Ipswich Mgmt, a Massachusetts-based fund reported 5,936 shs. Wealthtrust Axiom Lc holds 920 shs or 0.11% of its capital. First Mercantile Tru Com reported 7,977 shs. Advsrs Asset Mngmt has invested 0.07% in Biogen Inc. (NASDAQ:BIIB). Oregon Pub Employees Retirement Fund has invested 0.29% in Biogen Inc. (NASDAQ:BIIB). Field And Main State Bank has 300 shs. Ssi Management has invested 0.02% of its capital in Biogen Inc. (NASDAQ:BIIB). Old Mutual Customised Solutions (Proprietary) Limited invested in 11,695 shs or 0.38% of the stock. Los Angeles Capital Management And Equity owns 260,090 shs or 0.45% of their US capital.

BIIB registered $10.09 million net activity with 1 insider purchase and 5 insider sales since January 9, 2018. 259 Biogen Inc. (NASDAQ:BIIB) shs with value of $75,325 were sold by Sandrock Alfred. PANGIA ROBERT W had sold 5,832 shs worth $1.92 million on Tuesday, January 9.

Based on the latest 2017Q4 regulatory filing with the SEC, Primecap Management Company reduced its holdings in Biogen Inc. (BIIB) by 0.68%. The company’s stock declined 17.01% with the market as Primecap Management Company sold 103,683 shares. The biological products (no diagnostic substances) company at the end of 2017Q4 was valued at $4.81 billion. It’s down from 15.21M at the end of the previous reported quarter. Now it had 15.11 million shares held by the institutional investor . $59.58B is the market cap of Biogen Inc.. BIIB reached $282.34 during the last trading session after $6.28 change.Biogen Inc. has volume of 1.05 million shares. Since May 16, 2017 BIIB has declined 3.66% and is downtrending. BIIB underperformed by 15.21% the S&P 500.

Primecap Management Company manages about $87.86 billion and $130.31 billion US Long portfolio. According to a filing the fund rose its stake in Zimmer Biomet Holdings (ZMH) by 207,000 shares to 868,100 shares, valued at $104.75 million in 2017Q4. Primecap Management Company has risen its stake in Merck & Company (NYSE:MRK) and also increased its holding in Boeing Co. (NYSE:BA) by 38,100 shares in the quarter, for a total of 1.29M shares.

Biogen Inc. (NASDAQ:BIIB)’s earnings report is awaited on July, 24., according to RTT. earnings per share of $5.32 is 5.56 % up from 2017’s $5.04 EPS. If the current earnings per share of $5.32 is accurate, BIIB’s profit could reach $1.12 billion. -12.07 % negative EPS growth is what analysts predict. $6.05 earnings per share was reported for last quarter.

For more Biogen Inc. (NASDAQ:BIIB) news brought out recently go to: Seekingalpha.com, Seekingalpha.com, Seekingalpha.com, Fool.com or Seekingalpha.com. The titles are as follows: “Biogen Q1 2018: Too Cheap To Ignore” brought out on April 25, 2018, “Biogen’s Ionis Deal Is Brilliant” on April 25, 2018, “Biogen Buy Signal: Alzheimer’s Royalties Option” with a publish date: May 02, 2018, “Better Buy: Amgen Inc. vs. Biogen Inc.” and the last “Biogen: Down Too Far, Too Fast?” with publication date: April 25, 2018.

Biogen Inc. (NASDAQ:BIIB) Ratings Coverage

Total analysts of 25 have positions in Biogen Inc (NASDAQ:BIIB) as follows: 17 rated it a “Buy”, 0 with “Sell” and 8 with “Hold”. The positive are 68%. Since November 27, 2017 according to StockzIntelligence Inc Biogen Inc has 43 analyst reports. The company rating was maintained by BMO Capital Markets on Monday, March 5. The stock rating was maintained by Mizuho with “Buy” on Sunday, February 4. On Tuesday, April 24 the firm has “Buy” rating given by Guggenheim. On Wednesday, April 25 the rating was maintained by Leerink Swann with “Hold”. On Wednesday, May 2 the firm earned “Neutral” rating by Citigroup. In Thursday, January 25 report Cowen & Co maintained it with “Buy” rating and $408.0 target. The company rating was downgraded by Barclays Capital on Thursday, April 5. In Thursday, January 25 report Jefferies maintained it with “Hold” rating and $375.0 target. The stock rating was upgraded by Credit Suisse to “Buy” on Wednesday, December 20. On Tuesday, January 2 the firm has “Buy” rating by BMO Capital Markets given.

Biogen Inc. (NASDAQ:BIIB) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.